---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000055"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-05-20T23:59:59+00:00"
generated_at: "2026-05-21T00:25:33.241922+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# AEON Biopharma presents corporate update at Aegis Capital Conference, focusing on PrabotulinumtoxinA

## Summary
- Presentation highlights PrabotulinumtoxinA as a therapeutic botulinum toxin product candidate.
- Corporate presentation made available on AEON's investor relations website on May 20, 2025.
- No specific clinical data, financial results, or material changes disclosed in the furnished slides.

## SEC filing metadata
- accession: 0001837607-25-000055
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000055/0001837607-25-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000055/aeon-20250520x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000055
- JSON: https://secwatch.observer/filing/0001837607-25-000055.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.